Literature DB >> 31447410

Personalising osteoporosis treatment for patients at high risk of fracture.

Sundeep Khosla1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31447410      PMCID： PMC7082959          DOI： 10.1016/S2213-8587(19)30266-9

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  8 in total

1.  Drugs for Postmenopausal Osteoporosis.

Authors: 
Journal:  JAMA       Date:  2019-06-11       Impact factor: 56.272

Review 2.  Osteoporosis treatment: recent developments and ongoing challenges.

Authors:  Sundeep Khosla; Lorenz C Hofbauer
Journal:  Lancet Diabetes Endocrinol       Date:  2017-07-07       Impact factor: 32.069

3.  Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials.

Authors:  Mary L Bouxsein; Richard Eastell; Li-Yung Lui; Lucy A Wu; Anne E de Papp; Andreas Grauer; Fernando Marin; Jane A Cauley; Douglas C Bauer; Dennis M Black
Journal:  J Bone Miner Res       Date:  2019-01-23       Impact factor: 6.741

4.  Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.

Authors:  Joy N Tsai; Hang Lee; Natalie L David; Richard Eastell; Benjamin Z Leder
Journal:  Lancet Diabetes Endocrinol       Date:  2019-08-22       Impact factor: 32.069

5.  Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.

Authors:  Richard Eastell; Clifford J Rosen; Dennis M Black; Angela M Cheung; M Hassan Murad; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2019-05-01       Impact factor: 5.958

6.  Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

Authors:  Joy N Tsai; Alexander V Uihlein; Hang Lee; Ruchit Kumbhani; Erica Siwila-Sackman; Elizabeth A McKay; Sherri-Ann M Burnett-Bowie; Robert M Neer; Benjamin Z Leder
Journal:  Lancet       Date:  2013-05-15       Impact factor: 79.321

7.  High Generic Drug Prices and Market Competition: A Retrospective Cohort Study.

Authors:  Chintan V Dave; Aaron S Kesselheim; Erin R Fox; Peihua Qiu; Abraham Hartzema
Journal:  Ann Intern Med       Date:  2017-07-04       Impact factor: 25.391

8.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507
  8 in total
  3 in total

1.  Study on the influence of balloon dilation mode on the intravertebral cleft of osteoporotic fracture.

Authors:  Nanning Lv; Xiaoxiao Feng; Haojun Liu; Xuejun Jia; Shanqin Han; Mingming Liu
Journal:  BMC Surg       Date:  2022-09-30       Impact factor: 2.030

2.  A service evaluation of e-triage in the osteoporosis outpatient clinic-an effective tool to improve patient access?

Authors:  John R Lindsay; G Lawrenson; S English
Journal:  Arch Osteoporos       Date:  2020-03-21       Impact factor: 2.617

3.  Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study.

Authors:  E V McCloskey; H Johansson; N C Harvey; M Lorentzon; Y Shi; J A Kanis
Journal:  Osteoporos Int       Date:  2021-02-03       Impact factor: 4.507
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.